Adinazolam
Grundinformationen
- CAS
37115-32-5- Standard-SMILES
CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2- InChIKey
GJSLOMWRLALDCT-UHFFFAOYSA-N- Summenformel
- C19H18ClN5
- Durchschnittliche Molmasse
- 351,8 g/mol
- Monoisotopische Masse
- 351,1250733
Namen und Bezeichner
- Bevorzugter Name
- Adinazolam
- IUPAC
- 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine
- Englischer Name
- ADINAZOLAM
- Summenformel
- C19H18ClN5
- Molmasse
- 351.83
Namen und Synonyme
ADINAZOLAM37115-32-5AdinazolamumU-411238-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepineDTXSID40190611U-41,123KN08449444CHEBI:2514128-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine((12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo(8.4.0.0^(2,6))tetradeca-1(10),3,5,8,11,13-hexaen-3-yl)methyl)dimethylamine({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)dimethylamine
Weitere Namen anzeigen
Adinazolam (CRM)Adinazolam solution8-Chloro-N,N-dimethyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-1-methanamine4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-1-methanamine, 8-chloro-N,N-dimethyl-6-phenyl-γ-Aminobutyric acid Receptor,sickness,antihistamine,GABA Receptor,inhibit,Adinazolam,U-41123,U 41123,Huntington,Gamma-aminobutyric acid Receptor,anti-motion,piperazine,U41123,Inhibitor
RefChem:553043DTXCID80113102N05BA07Adinazolamum [INN-Latin]Deracyn1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamineU 41123Adinazolam [USAN]
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 1,6
- Polarare Oberfläche (TPSA)
- 46,3 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 4
- Frei drehbare Bindungen
- 3
- Schwere Atome
- 25
- Formalladung
- 0
- Komplexität
- 490
Experimentelle und physikochemische Eigenschaften
LogP
4.4
4.4
Solubility6.72e-02 g/L
Physical DescriptionSolid
Kovats Retention Index3060
Physikochemische Eigenschaften
- Schmelzpunkt
- 171 · 171-172.5° (US 4250094); mp 165-166° (DE 2201210)
- Siedepunkt
- 527 · 527.0±60.0 °C(Predicted)
- Dichte
- 1.31 · 1.31±0.1 g/cm3(Predicted)
- storage temp.
- -10 to · -10 to -25°C
- Aggregatzustand
- Solid
- pka
- 6.2 · pKa 6.2 (D2O/DClor D2O/NaOD ) (Uncertain);5.8±0.1(D2O/DClor D2O/NaOD ) (Uncertain)
- Farbe
- White to off-white
- InChI
- 1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3
Sicherheit und Regulatorisches
Sicherheitsdaten
- wgk
- WGK 2
- ridadr
- 3249
- hazard_class
- 6.1(b)
- packing_group
- III
- Speicherklasse
- 3 - Flammable liquids
- Hazard Classifications
- Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 OralEye Irrit. 2Flam. Liq. 2
Chemie und Industrie
Pharmakologische Informationen
ATC Code
N - Nervous system；N05 - Psycholeptics；N05B - Anxiolytics；N05BA - Benzodiazepine derivatives；N05BA07 - Adinazolam
QN - Nervous system；QN05 - Psycholeptics；QN05B - Anxiolytics；QN05BA - Benzodiazepine derivatives；QN05BA07 - Adinazolam
Pharmacodynamics
Adinazolam is a benzodiazepine derivative used to treat anxiety, status epilepticus, and for sedation induction and anterograde amnesia. Adinazolam binds with high affinity to the GABA benzodiazepine receptor complex. Considerable evidence suggest that the central pharmacologic/therapeutic actions of alprazolam are mediated via interaction with this receptor complex.
Mechanism of Action
Adinazolam binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
Biological Half-LifeLess than 3 hours.
Metabolism/Metabolites
The drug primarily undergoes hepatic metabolism to form the main metabolite N-desmethyladinazolam, alpha-hydroxyalprazolam, and estazolam.
Adinazolam has known human metabolites that include N-demethyladinazolam.
MeSH Pharmacological Classification
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
Zugehörige Reaktionen
5
Notizen zur Verbindung
Wird geladen…